Trump Signs Executive Order Fast-Tracking Psychedelic Drug Research for Veterans

President Trump signed an executive order on April 17, 2026 directing the FDA to fast-track reviews and expand access to psychedelic drugs — including psilocybin, ibogaine, LSD, and MDMA — specifically citing mental health treatment for veterans with PTSD and depression. The signing ceremony in the Oval Office included HHS Secretary RFK Jr., podcast host Joe Rogan, and senior federal health officials. The FDA simultaneously announced the first ibogaine investigational new drug clearance, paving the way for US human clinical trials. The DEA and DOJ were directed to initiate rescheduling reviews for any Schedule I substance completing successful Phase 3 clinical trials. The move represented a significant shift in US drug policy, with bipartisan support from veterans advocacy groups.